TGTX Q3 2020 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$38,000+0.0% YoY

Gross Profit

$38,000100.0% margin

Operating Income

-$86M-225584.2% margin

Net Income

-$87M-229376.3% margin

EPS (Diluted)

$-0.73

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$57M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$274M

Total Liabilities

$103M

Stockholders' Equity

$171M

Cash & Equivalents

$254M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$38,000	$38,000	+0.0%
Gross Profit	$38,000	$38,000	+0.0%
Operating Income	-$86M	-$61M	-40.8%
Net Income	-$87M	-$62M	-40.7%